Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 10/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.44 |
| ▸ | LCAT | P04180 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | CLK3 | P49761 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16648672 | 0.82 | MAP4K4 (0.49) | PIM1PIM3PIM2LCATDRD2 | |
| SCHEMBL16648829 | 0.79 | GPR119 (0.44) | LCATDRD2DRD4DRD3MAP4K4 | |
| SCHEMBL16648414 | 0.75 | LCAT (0.46) | LCATDRD2DRD4DRD3HTT | |
| SCHEMBL16648762 | 0.75 | LCAT (0.46) | LCATDRD2DRD4DRD3 | |
| SCHEMBL16648536 | 0.73 | CHRNB2 (0.51) | LCATLMNAHTTSMN1; SMN2 | |
| SCHEMBL16648647 | 0.73 | LCAT (0.49) | LCATSMN1; SMN2NPSR1 | |
| SCHEMBL16648618 | 0.73 | LCAT (0.48) | LCATDRD2DRD4DRD3MAP4K4 | |
| SCHEMBL16648527 | 0.72 | LCAT (0.44) | PIM1LCATMAP4K4S1PR2LMNA | |
| SCHEMBL16648795 | 0.72 | LCAT (0.45) | LCATDRD2DRD4DRD3S1PR2 | |
| SCHEMBL16648748 | 0.72 | LCAT (0.45) | LCATDRD2DRD4DRD3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862861-B1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| EP-2862861-B1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2862861-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862861-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | LCAT, LPL, LCLAT1 | PIM1 1553/4885PIM3 1555/4885PIM2 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.